Pharmaceuticals: suspected anti-competitive agreements and conduct

The CMA is investigating alleged anti-competitive agreements and abusive conduct in the pharmaceutical sector under Chapters I and II CA98 and Articles 101 and 102 TFEU.

Case timetable

Date Action
November 2018 to January 2019 (estimate) Further investigation and analysis including information gathering and stakeholder meetings
July 2018 to November 2018 Further investigation and analysis including information gathering and stakeholder meetings
July 2018 Decision to continue with the investigation
May 2018 to July 2018 Investigation and analysis including further information gathering
October 2017 to April 2018 Initial investigation, information gathering, including issuance of formal or information requests and parties’ responses. CMA analysis and review of parties’ responses to information requests. Potential state of play meetings with parties under investigation
October 2017 Investigation opened

Change log

The following changes have been made to the case timetable since it was first published in October 2017:

Date of change Reason for change Change made to timetable
1 August 2018 Additional time needed for further information gathering and to hold stakeholder meetings Date for holding stakeholder meetings changed from May 2018 to July 2018 to July 2018 to November 2018 (estimate)

Case information

On 18 October 2017, the Competition and Markets Authority (CMA) launched an investigation under Chapters I and II of the Competition Act 1998 (CA98) and Articles 101 and 102 of the Treaty on the Functioning of the European Union (TFEU) into suspected breaches of competition law by various parties. The investigation relates to suspected anti-competitive agreements and/or concerted practices and suspected abuse of dominance in relation to the supply of certain generic pharmaceutical products.

The CMA has not reached a view on whether there is sufficient evidence of an infringement of competition law for it to issue a statement of objections to the parties under investigation. Not all cases result in the CMA issuing a statement of objections.

Further detail of the CMA’s procedures in CA98 cases is available in our guidance.

Contacts

Assistant Project Director

Karina Kucaidze (020 3738 6730, karina.kucaidze@cma.gov.uk)

Project Director

Sue Aspinall (020 3738 6788, sue.aspinall@cma.gov.uk)

Senior Responsible Officer

Andrew Groves (020 3738 6927, andrew.groves@cma.gov.uk)

Published 18 October 2017
Last updated 1 August 2018 + show all updates
  1. Updated case timetable and change log published.
  2. Updated case timetable and change log published.
  3. Case timetable updated.
  4. First published.